Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track

Design Therapeutics, Inc.

2026-Q1 EPS reported -$0.29

Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.
Cash, equivalents and securities total $222.8M as of March 31, 2026, providing runway to 2029.
DT-216P2 Phase 1/2 RESTORE-FA trial dosing continues; frataxin update expected H2 2026.
DT-168 Phase 2 FECD trial ongoing with data in H2 2026; DT-818 DM1 Phase 1 MAD trial to begin dosing H1 2026.
David Shapiro, M.D., appointed to board of directors in March 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Design Therapeutics, Inc. reported the three months ended March 31, 2026 results: net income Net loss was $17.6 million for the quarter ended March 31, 2026..

Period: the three months ended March 31, 2026
Net income: Net loss was $17.6 million for the quarter ended March 31, 2026.
Result: reported results

Exact text from the filing

Net loss was $17.6 million for the quarter ended March 31, 2026.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-187012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.